期刊文献+

PSMA、PSA在前列腺腺癌组织中的表达及其与腺癌临床分期的相关性分析 被引量:8

Expression of prostate specific membrane antigen and prostate specific antigen in prostatic adenocarcinoma tissue and its correlation with clinical stages of prostatic adenocarcinoma
在线阅读 下载PDF
导出
摘要 目的:研究前列腺腺癌(Pca)组织中前列腺特异性膜抗原(PSMA)、前列腺特异性抗原(PSA)的表达差异,评价两者在Pca预后评估中的价值。方法:选取Pca患者70例,平均年龄(74.3±6.1)岁;前列腺增生(BPH)患者62例,平均年龄(72.1±6.1)岁。采用免疫组化法检测PSMA、PSA表达。结果:Pca患者PSMA、PSA表达阳性率分别为61.4%(43/70)、91.4%(64/70);BPH患者分别为9.7%(6/62)、90.3%(56/62)。PSMA在Pca与BPH中的表达差异有显著性(P<0.001),PSA在Pca与BPH中的表达差异无显著性(P>0.05)。PSMA、PSA表达对Pca的检出率差异有显著性(P<0.001)。采用Spearman等级相关分析显示,PSMA和PSA在Pca中的表达无相关性(P=0.606);Pca临床分期与PSMA表达呈正相关(r=0.66,P<0.001),而与PSA表达无相关性(P=0.683)。结论:PSMA和PSA均有较好的前列腺组织特异性,组织PSA在鉴别男性肿瘤来源时较PSMA存在一定的优势;在鉴别前列腺组织病变的良、恶性时,PSMA优于PSA。PSMA表达与Pca的临床分期存在相关性,是Pca预后评价的重要指标之一,而组织PSA表达未显示这一优势。 Objective:To study the difference of expression of prostate specific membrane antigen(PSMA) and prostate specific antigen(PSA) in prostatic adenocarcinoma tissue and to evaluate their clinical value in the prognosis of prostate cancer.Methods:70 patients of prostatic adenocarcinoma(Pca) with an average age of(74.3±6.1) years old and 62 patients of benign prostate hyperplasia(BPH) with an average age of(72.1±6.1) years old were enrolled in this study.The expression of PSMA and PSA were determined by immunohistochemical staining.Results:Positive expression rates of PSMA and PSA in patients with Pca were 61.4%(43/70),91.4%(64/70) respectively;and positive rates of PSMA and PSA in patients with BPH were 9.7%(6/62),90.3%(56/62) respectively.The expression of PSMA between Pca and BPH(P0.001) was significantly different,but the expression of PSA between Pca and BPH(P0.05)was not significantly different.The detection rates of Pca between PSMA and PSA(P0.001) were significantly different.By spearman rank correlation analysis,expression of PSMA and PSA in Pca showed no correlation(P=0.606).Clinical stages of Pca was positively correlated with the expression of PSMA(r=0.66,P0.001),but not correlated with the expression of PSA(P=0.683) did not show any correlation.Conclusion:PSMA and PSA have better prostatic tissue specificity.Expression of PSA in identifying sources of tumors in males and has some advantages over that of PSMA,but in the differential diagnosis of prostatic tissue of benign and malignant,PSMA is better than PSA.Expression of PSMA,one of the important indicators in prognosis of Pca,has a positive correlation(r=0.66,P0.001) with clinical stages of Pca while the expression of PSA has not.
出处 《东南大学学报(医学版)》 CAS 2010年第1期65-69,共5页 Journal of Southeast University(Medical Science Edition)
关键词 前列腺腺癌 前列腺特异性膜抗原 前列腺特异性抗原 免疫组织化学 临床分期 prostatic adenocarcinoma prostate specific membrane antigen prostate specific antigen immunohischemistry clinical stages
作者简介 唐庆来(1978-),男,江苏姜堰人,主治医师,硕士。E—mail:qinglaitang@hotmail.com
  • 相关文献

参考文献4

二级参考文献28

  • 1Rinker-Scaeffer, Havkin CW. Location and physical mapping of the PSMA gene to human chromosome 11, Genonics, 1995,30 : 105-108.
  • 2Heston WD. Significance of PSMA. Urology, 1996,35:400-407.
  • 3Carter RE, Feldman AR, Colye ,IT. PSMA is a hydrolase with substrate and pharmacologic characterizations of nearapeptidose. Nat Acad Sci USA, 1996,39:749-753.
  • 4Fair WR, Israeli RS, Heston WD. Prostate-specific membrane antigen. Prostate, 1997,32 : 140-148.
  • 5Bostwick DC, Michael B, Pacelli A,et al. Prostate specific membrane antigen expression in PIN and adenocarcinoma. Cancer, 1998,82 :2256-2261.
  • 6Isaceli RS, Miller WH, Su SL, et al. Sensitive nested transcription polymerase chain reaction detection of circulating prostate tumor cells:comparsion of PSMA and PSA based assay. Cancer Res, 1994,54:6306-6310.
  • 7Silver DA, Pellicer I, Fair WR, et al. Prostatic-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res, 1997,3:81-85.
  • 8Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelia neoplasia and adenocarcinoma. Am Cancer Soci, 1998,1:2256-2261.
  • 9Burger JK, Hinkle GH, Nelsun CM,et al. Monoclonal antibody imaging of recurrent and metastasic prostate cancer. Urology, 1995,13 :103-112.
  • 10Polasick TJ, Gurganus RT, Partin AW, et al. Comparsion of staging algorithus and a monoclonal antibody scan to predict lymphnode involvement in high-risk prostate cancer. J Urel, 1998,59:289.

共引文献46

同被引文献77

引证文献8

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部